Literature DB >> 14755613

Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development.

Showchien Hsieh1, Tom Tobien, Kevin Koch, John Dunn.   

Abstract

An approach is described with turbulent flow on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) for GLP quantitative bioanalysis of a drug candidate. Two systems were built in-house with standard laboratory parts and equipments. One system consisted of one gradient HPLC pump, one isocratic pump, one ten-port valve, two turbulent flow columns, one analytical column, one autosampler and one mass spectrometer. Using this system, an injection-to-injection cycle time of 0.8 min was achieved. By adding an additional valve, another analytical column and an isocratic pump, the injection-to-injection cycle time decreased to 0.4 min. Validation results from the two systems showed that precision and accuracy were acceptable for GLP quantitative analyses. The system was utilized to support sample bioanalysis of a drug candidate in a first-time in-human clinical trial. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755613     DOI: 10.1002/rcm.1327

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  16 in total

1.  Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.

Authors:  Aimee K Bence; Eric B Anderson; Maqbool A Halepota; Michael A Doukas; Phillip A DeSimone; George A Davis; Deborah A Smith; Kevin M Koch; Andrew G Stead; Steve Mangum; Carolyn J Bowen; Neil L Spector; Showchien Hsieh; Val R Adams
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

2.  Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.

Authors:  Julian R Molina; Scott H Kaufmann; Joel M Reid; Stephen D Rubin; Marina Gálvez-Peralta; Robert Friedman; Karen S Flatten; Kevin M Koch; Tona M Gilmer; Robert J Mullin; Roxanne C Jewell; Sara J Felten; Sumithra Mandrekar; Alex A Adjei; Charles Erlichman
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

3.  Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.

Authors:  Maja J A de Jonge; Paul Hamberg; Jaap Verweij; Shawna Savage; A Benjamin Suttle; Jeffrey Hodge; Thangam Arumugham; Lini N Pandite; Herbert I Hurwitz
Journal:  Invest New Drugs       Date:  2012-10-06       Impact factor: 3.850

4.  Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.

Authors:  Shirish M Gadgeel; Danika L Lew; Timothy W Synold; Patricia LoRusso; Vincent Chung; Scott D Christensen; David C Smith; Laura Kingsbury; Antje Hoering; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2013-09-22       Impact factor: 3.333

5.  Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies.

Authors:  Nils Helge Schebb; Bora Inceoglu; Tristan Rose; Karen Wagner; Bruce D Hammock
Journal:  Anal Methods       Date:  2011-01-01       Impact factor: 2.896

6.  Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.

Authors:  Charles A Kunos; Steven Waggoner; Vivian von Gruenigen; Elisa Eldermire; John Pink; Afshin Dowlati; Timothy J Kinsella
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

7.  Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

Authors:  Dhara N Amin; Natalia Sergina; Deepika Ahuja; Martin McMahon; Jimmy A Blair; Donghui Wang; Byron Hann; Kevin M Koch; Kevan M Shokat; Mark M Moasser
Journal:  Sci Transl Med       Date:  2010-01-27       Impact factor: 17.956

8.  EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.

Authors:  Deliang Guo; Robert M Prins; Julie Dang; Daisuke Kuga; Akio Iwanami; Horacio Soto; Kelly Y Lin; Tiffany T Huang; David Akhavan; M Benjamin Hock; Shaojun Zhu; Ava A Kofman; Steve J Bensinger; William H Yong; Harry V Vinters; Steve Horvath; Andrew D Watson; John G Kuhn; H Ian Robins; Minesh P Mehta; Patrick Y Wen; Lisa M DeAngelis; Michael D Prados; Ingo K Mellinghoff; Timothy F Cloughesy; Paul S Mischel
Journal:  Sci Signal       Date:  2009-12-15       Impact factor: 8.192

9.  Effects of food on the relative bioavailability of lapatinib in cancer patients.

Authors:  Kevin M Koch; Nandi J Reddy; Roger B Cohen; Nancy L Lewis; Bonnie Whitehead; Kathleen Mackay; Andrew Stead; Andrew P Beelen; Lionel D Lewis
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

10.  A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.

Authors:  Amy J Chien; Julie A Illi; Andrew H Ko; Wolfgang M Korn; Lawrence Fong; Lee-may Chen; Mohammed Kashani-Sabet; Charles J Ryan; Jonathan E Rosenberg; Sarita Dubey; Eric J Small; Thierry M Jahan; Nola M Hylton; Benjamin M Yeh; Yong Huang; Kevin M Koch; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.